Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (475)	1/24/1998 12:31:00 PM
From: 5,17,37,5,101,...	Read Replies (2) \| Respond to of 756

A little supplemental information would be of great assistance. Generic Prochlorperazine was approved for Mylan 11/96: centerwatch.com **************************************************** excerpt from a 5/97 Cincinnati Inquirer article... Compazine has annual sales of about $55 million, Mr. Arington [CEO Duramed] said, but he would not estimate Duramed's potential slice of the market. ''It's our opinion that two-thirds of the market should go to the generic participants, and you can take your own guess at how good we are,'' he said. enquirer.com ****************************************************************** So the low cost producer of Mylan, Duramed, and Ivax will see revenue of about $30 to $40 million per year plus growth. This, as I thought, is not a lot. HOWEVER, Mylan and Duramed were down 5+% and 2+%, respectively, on Friday, while the rest of the generic drug group did not do badly. Let's have the real news. Jackson